APM
XENE icon

Avidity Partners Management’s Xenon Pharmaceuticals XENE Stock Holding History

Avidity Partners Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-53,400
Closed -$2.14M – 52
2025
Q3 		$2.14M Sell
53,400
-54,491
-51% -$1.92M 0.49% 39
2025
Q2 		$3.38M Sell
107,891
-121,109
-53% -$3.95M 0.67% 39
2025
Q1 		$7.68M Sell
229,000
-245,000
-52% -$9.3M 1.46% 25
2024
Q4 		$18.6M Sell
474,000
-344,000
-42% -$14.2M 1.82% 24
2024
Q3 		$32.2M Buy
818,000
+64,000
+8% +$2.58M 1.64% 25
2024
Q2 		$29.4M Buy
754,000
+44,000
+6% +$1.76M 1.25% 31
2024
Q1 		$30.6M Sell
710,000
-105,993
-13% -$4.88M 0.99% 36
2023
Q4 		$37.6M Buy
815,993
+494,593
+154% +$17.5M 1.37% 34
2023
Q3 		$11M Sell
321,400
-159,900
-33% -$5.98M 0.44% 66
2023
Q2 		$18.5M Buy
+481,300
New +$19.1M 0.65% 55
2022
Q3 		– Sell
-450,000
Closed -$13.7M – 108
2022
Q2 		$13.7M Buy
+450,000
New +$13.6M 0.31% 46

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Avidity Partners Management's XENE Position: Q4 2025 in Review

Avidity Partners Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 53,400 shares — an estimated $2.14M sold.

Avidity Partners Management first reported a position in XENE in Q2 2022 and held it in 11 quarters. The position peaked at $37.6M in Q4 2023. 245 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Avidity Partners Management reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Avidity Partners Management sold 53,400 Xenon Pharmaceuticals shares in Q4 2025, an estimated $2.14M.
  • Avidity Partners Management first reported a position in Xenon Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Avidity Partners Management's Xenon Pharmaceuticals position peaked at $37.6M in Q4 2023.
  • 245 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.